In the News

1855 News Items found
Gloved hand and magnifying glass on banded DNA sequences
Announcement
The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.
Prostate cancer cells, colored red in scanning electron micrograph (SEM).
Science Byte
Researchers have discovered how a high level of the protein PSMA in cells helps fuel prostate cancer.
MSK Director of Breast Pathology Edi Brogi
Q&A
Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.
Former MSK president Paul Marks
Feature
Recent advances in epigenetic and targeted therapies owe a lot to the foresight of former MSK President Paul Marks, who believed in the importance of basic research.
Thanksgiving dinner
Feature
Read our suggestions for getting through the holiday season while facing cancer.
The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as a direct result of research at Memorial Sloan Kettering Cancer Center (MSK).
iron-filled macrophages from a breast cancer tumor
In the Lab
The noninvasive approach could help scientists track the movements of an important cell type that can influence the outcome of cancer treatment.
Cancer biologist and pediatric oncologist Alex Kentsis
Science Byte
A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.
Shawn, a Fred’s Team runner
Event
Hear from five Fred’s Team members about why they’re running the New York City Marathon in 2017.
MSK Integrative Medicine meditation instructor Emily Herzlin
Q&A
Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.